Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI

Korábbi kezelés

• Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)
• Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

Más betegség

• Active current autoimmune disease or history of autoimmune disease
• Known HIV positive or chronically active hepatitis B or C

Egyéb

• Administration of other investigational medicinal product within 30 days of screening

• Subject is > 18 years of age
• Clinical and radiological diagnosis of metastatic cancer with histological verification.
• White blood cell count: > 2.0 x 10\^9/L
• Haemoglobin: > 80 g/L
• Platelets: > 50.0 x 10\^9/L
• Bilirubin =< 2.0 times Upper Limit of Normal
• Serum creatinine: Within Normal Limits
• Blood glucose level not more than 5.9 mmol/L
• A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination
• Subject is capable to undergo the diagnostic investigations to be performed in the study
• Informed consent